Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 5
Submit an article Journal homepage
282
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting

R. Malessa Sopien- und Hufeland-Klinikum, Henry-van-de-Velde-Str. 2, 99425 Weimar, GermanyCorrespondence[email protected]
,
A. Gendolla Schmerzpraxis, 1. Hagen 26, 45147 Essen, Germany, current address: Schwermannstr. 6, 45257 Essen, Germany
,
B. Steinberg Schmerzpraxis, Am Sooren 1a, 22149 Hamburg, Germany
,
L. Schmitt Schmerzpraxis, Gesundheitshaus Karl Schneider Passagen, Heussweg 37, 20255 Hamburg-Eimsbuettel, Germany
,
K. Bornhoevd Janssen-Cilag EMEA, Neuss, Johnson and Johnson Platz 5a, 41470 Neuss, Germany
,
M. Djelani Janssen-Cilag, Raiffeisenstrasse 8, 41470 Neuss, Germany
,
B. Schäuble Janssen-Cilag EMEA, Neuss, Johnson and Johnson Platz 5a, 41470 Neuss, Germany
& on behalf of the TOPMAT-MIG-3004 investigators show all
Pages 1119-1129 | Accepted 04 Feb 2010, Published online: 15 Mar 2010

References

  • Silberstein SD, Lipton RB. Epidemiology of migraine. Neuroepidemiology 1993;12:179-94
  • Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States – relation to age, race, income, and other sociodemographic factors. JAMA 1992;267:64-9
  • Hazard E, Munakata J, Bigal ME, et al. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health 2009;12:55-64
  • Andlin-Sobocki P, Jönsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12(Suppl 1):1-27
  • Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
  • Diener HC, Brune K, Gerber WD, et al. Therapy of the acute migraine attack and migraine prophylaxis. Recommendation of the Deutsche Migrane- und Kopfschmerz- Gesellschaft. Schmerz 2000;14:269-83
  • Evers S, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
  • Géraud G, Lantéri-Minet M, Lucas C, et al. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004;26:1305-18
  • Evans RW, Rizzoli P, Loder E, et al. Beta-blockers for migraine. Headache 2008;48:455-60
  • Schürks M, Diener H-C, Goadsby P. Update on the prophylaxis of migraine. Curr Treat Options Neurol 2008;10:20-9
  • Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008;28:585-97
  • Fontebasso M. Topiramate for migraine prophylaxis. Expert Opin Pharmacotherapy 2007;8:2811-23
  • Diener HC, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009;10:1021-7
  • Silberstein SD, Neto W, Schmitt J, et al.; for the MIGR-0001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-5
  • Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention – a randomized controlled trial. JAMA 2004;291:965-73
  • Diener HC, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-50
  • Lipton RB, Stewart WF, Sawyer J, et al. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001;41:854-61
  • Ware JE Jr, Bjorner JB, Kosinski M. Practical implications of item response theory and computerized adaptive testing: a brief summary of ongoing studies with widely used headache impact scales. Med Care 2000;38:1173-82
  • Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, second edition (ICHD-II). Cephalalgia 2004;24(Suppl 1):1-160
  • Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo controlled study. Cephalalgia 2007;27:814-23
  • Dahlöf C, Loder E, Diamond M, et al. The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes 2007;5:56-66
  • Rapoport A, Mausko PA, Diener HC, et al. Long-term migraine prevention with topiramate: open label extension of pivotal trials. Headache 2006;46:1151-60
  • Nelles G, Delbrück A, Schulze L; on behalf of the TOPMAT-MIG-4009 Investigators Group. Topiramate for migraine prevention in a naturalistic setting- results from an open-label, flexible dose study. Headache 2009;49:1454-65
  • Láinez MJA, Freitag FG, Pfeil J, et al. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol 2007;14:900-6
  • Ford ES, Li C, Pearson WS, et al. Body mass index and headaches: findings from a national sample of US adults. Cephalalgia 2008;28:1270-6
  • Taylor FR. Weight change associated with the use of migraine-preventive medications. Clin Ther 2008;30:1069-80
  • Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American migraine prevalence study. Headache 2007;47:355-63

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.